1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013

Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Cytokine PharmaSciences, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Cytokine PharmaSciences, Inc. - Product Pipeline Review - 2013” provides data on the Cytokine PharmaSciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cytokine PharmaSciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cytokine PharmaSciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cytokine PharmaSciences, Inc. - Brief Cytokine PharmaSciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cytokine PharmaSciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cytokine PharmaSciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cytokine PharmaSciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cytokine PharmaSciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cytokine PharmaSciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cytokine PharmaSciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cytokine PharmaSciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cytokine PharmaSciences, Inc. and identify potential opportunities in those areas.

Table Of Contents

Cytokine PharmaSciences, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Cytokine PharmaSciences, Inc. Snapshot 5
Cytokine PharmaSciences, Inc. Overview 5
Key Information 5
Key Facts 5
Cytokine PharmaSciences, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Cytokine PharmaSciences, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Cytokine PharmaSciences, Inc. - Pipeline Products Glance 11
Cytokine PharmaSciences, Inc. Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Cytokine PharmaSciences, Inc. - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Cytokine PharmaSciences, Inc. - Drug Profiles 13
Anti-MIF Receptor 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
clindamycin 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
IPFK-2 Inhibitors 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
MIF Inhibitors 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Next Nuclear Importation Inhibitors 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
semapimod 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Cytokine PharmaSciences, Inc. - Pipeline Analysis 19
Cytokine PharmaSciences, Inc. - Pipeline Products by Therapeutic Class 19
Cytokine PharmaSciences, Inc. - Pipeline Products by Route of Administration 20
Cytokine PharmaSciences, Inc. - Pipeline Products By Mechanism of Action 21
Cytokine PharmaSciences, Inc. - Recent Pipeline Updates 22
Cytokine PharmaSciences, Inc. - Locations And Subsidiaries 23
Head Office 23
Financial Deals Landscape 24
Cytokine PharmaSciences, Inc., Deals Summary 24
Cytokine PharmaSciences, Inc., Pharmaceuticals and Healthcare, Deal Details 25
Licensing Agreements 25
Marillion Pharma Enters Into Licensing Agreement With Cytokine PharmaSciences 25
Presidio Pharma Enters Into Licensing Agreement With Cytokine PharmaSciences 26
Acquisition 27
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 27
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



List of Tables

Cytokine PharmaSciences, Inc., Key Information 5
Cytokine PharmaSciences, Inc., Key Facts 5
Cytokine PharmaSciences, Inc. - Pipeline by Indication, 2013 8
Cytokine PharmaSciences, Inc. - Pipeline by Stage of Development, 2013 9
Cytokine PharmaSciences, Inc. - Monotherapy Products in Pipeline, 2013 10
Cytokine PharmaSciences, Inc. - Phase I, 2013 11
Cytokine PharmaSciences, Inc. - Pre-Clinical, 2013 12
Cytokine PharmaSciences, Inc. - Pipeline By Therapeutic Class, 2013 19
Cytokine PharmaSciences, Inc. - Pipeline By Route of Administration, 2013 20
Cytokine PharmaSciences, Inc. - Pipeline Products By Mechanism of Action, 2013 21
Cytokine PharmaSciences, Inc. - Recent Pipeline Updates, 2013 22
Cytokine PharmaSciences, Inc., Deals Summary 24
Marillion Pharma Enters Into Licensing Agreement With Cytokine PharmaSciences 25
Presidio Pharma Enters Into Licensing Agreement With Cytokine PharmaSciences 26
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 27



List of Figures

Cytokine PharmaSciences, Inc. - Pipeline by Indication, 2013 7
Cytokine PharmaSciences, Inc. - Pipeline by Stage of Development, 2013 9
Cytokine PharmaSciences, Inc. - Monotherapy Products in Pipeline, 2013 10
Cytokine PharmaSciences, Inc. - Pipeline By Therapeutic Class, 2013 19
Cytokine PharmaSciences, Inc. - Pipeline By Route of Administration, 2013 20
Cytokine PharmaSciences, Inc. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.